UK markets close in 2 minutes

Ultimovacs ASA (ULTIO.OL)

Oslo - Oslo Delayed price. Currency in NOK
Add to watchlist
110.200.00 (0.00%)
At close: 12:21PM CET
Full screen
Previous close110.20
Open109.60
Bid0.00 x N/A
Ask0.00 x N/A
Day's range110.20 - 110.20
52-week range110.20 - 110.20
Volume66
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer

    Study assesses impact of UV1 in ovarian cancer maintenance careAddresses unmet medical need among BRCA-negative ovarian cancer patients Enrollment of 184 patients to be coordinated through NSGO-CTU and ENGOT Oslo, 15 December 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today that the first patient has been enrolled in the DOVACC (Durvalumab Olaparib VACCine) study, a randomized Phase II clinical trial assessing the

  • Globe Newswire

    Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma

    Designation covers UV1 in Metastatic Melanoma as sole agent or part of combinationSeven-year market exclusivity after regulatory approval, if received Oslo, 2 December 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma. UV1, as add-on th

  • Globe Newswire

    Ultimovacs ASA: Mandatory notification of trade by primary insider

    Oslo, 2 December 2021, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at a price of NOK 107.60 per share. Following this transaction, Carlos de Sousa and closely related parties hold 15,056 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachment 2